08.29.17
MilliporeSigma has entered a collaboration with Angiex, Inc. to support the development of Angiex’s lead oncology antibody drug candidate for clinical use. Angiex is developing TM4SF1 as a potential therapy for cancer against a vascular target.
This collaboration is the first project to be undertaken at MilliporeSigma's new biodevelopment center in Burlington, MA, which will open in October 2017. MilliporeSigma will provide access to process development tools, education programs and training.
"Companies benefit from our expertise and experience in developing GMP manufacturing processes for early clinical development programs," said Udit Batra, chief executive officer, MilliporeSigma. "With an end-to-end approach, MilliporeSigma can facilitate and accelerate scaling and technical transfer for companies like Angiex."
Angiex chief executive officer, Dr. Paul Jaminet, said, "Through this collaboration, Angiex hopes to accelerate our path to the clinic. We appreciate MilliporeSigma's expertise in bringing to cancer patients an innovative treatment capable of addressing the most dangerous solid tumors."
This collaboration is the first project to be undertaken at MilliporeSigma's new biodevelopment center in Burlington, MA, which will open in October 2017. MilliporeSigma will provide access to process development tools, education programs and training.
"Companies benefit from our expertise and experience in developing GMP manufacturing processes for early clinical development programs," said Udit Batra, chief executive officer, MilliporeSigma. "With an end-to-end approach, MilliporeSigma can facilitate and accelerate scaling and technical transfer for companies like Angiex."
Angiex chief executive officer, Dr. Paul Jaminet, said, "Through this collaboration, Angiex hopes to accelerate our path to the clinic. We appreciate MilliporeSigma's expertise in bringing to cancer patients an innovative treatment capable of addressing the most dangerous solid tumors."